Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (1159)	12/22/2001 4:13:28 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Ed, You had asked earlier about projections for the Eligix and MEDI-507 products....sorry for not getting back to you sooner. One analyst has the following numbers for the Eligix products...remember these early numbers only reflect European revenue as it will be at least two years before approval here in the US. 2002E..$4,867,500 2003E..$9,645,000 2004E..$14,422,500 2005E..$20,317,500 2006E..$26,032,500 As for MEDI-507, we are probably looking at 2004 before revenue starts for this drug, but the market is huge...and lets not forget that Medimunne is scheduled to move the drug into Phase II testing in the early part of 2002 for psoriatic arthritis, rheumatoid arthritis and T cell lymphomas. And don't forget the AlloMune program! BTRN is scheduled to move this into Phase I/II for refractory lymphoma before the year is out....so if this is the case, we HAVE to get news next week. IMO the next big event will be the release of the Phase II psoriasis data and the start of the Phase III trials in the 2Q of 2002. It appears that there is much to be done and released within the first two Q of 2002. If all comes to fruition, who thinks it will still be a $7.00 stock?